(单词翻译:单击)
Pfizer's COVID-19 treatment Paxlovid will not be added to China's updated medical reimbursement list because the company asked for a very high price during the latest round of price negotiations that wrapped up on Sunday, the National Healthcare Security Administration said on Sunday.
国家医疗保障局周日表示，在周日结束的最新一轮价格谈判中，辉瑞公司生产的新冠病毒治疗药物Paxlovid因该公司报价高未能成功列入中国最新的医疗报销清单。
However, drugmakers of two other COVID-19 therapies — the homegrown Azvudine and the Qingfei paidu granule, a widely used traditional Chinese medicine to ease COVID-19 symptoms — have successfully struck a deal during the negotiation, said the administration.
然而，国家医疗保障局表示，另外两种缓解新冠肺炎症状的中药——阿兹夫定片和清肺排毒颗粒——谈判成功。
With the two additions, the administration said that the medical reimbursement list will contain more than 600 types of drugs that have been proven to alleviate fevers, coughing and other COVID-19 symptoms.
国家医疗保障局表示，阿兹夫定片、清肺排毒颗粒经过本次谈判纳入国家医保药品目录后，国家医保药品目录内治疗发热、咳嗽等新冠症状的药品已达600余种。
Local healthcare security authorities have also included a number of COVID-19 drugs to their temporary reimbursement lists based on the capacity of local funds.
各地医保部门结合当地医保基金运行情况，又将一批新冠对症治疗药物临时纳入本地区医保支付范围。
Although the highly-anticipated inclusion of Paxlovid was not achieved, the administration said that all COVID-19 drugs listed in the latest version of COVID-19 treatment protocol, including Paxlovid and Merck's Molnupiravir, will be reimbursed through to March 31.
尽管大家期待的辉瑞Paxlovid未能成功纳入清单，但国家医疗保障局表示，最新版本的新冠肺炎治疗方案中列出的所有药物，包括Paxlovid和默克公司研发的Molnupiravir，患者在2023年3月31日前均可享受到相关的医保报销政策。
"We have a rich variety of reimbursable drugs used to treat COVID-19," it said.
国家医疗保障局表示：“医保报销的新冠治疗用药品种丰富。”
